A rising focus on men's health issues, more sophisticated registry data and new techniques for
investigating the biology of cancers are fuelling interest in unravelling what lies behind
gender differences in cancer incidence and mortality. Getting answers could boost prevention
and early detection and could even lead to better targeted therapies.
Targeted therapies seek to close down signalling pathways that allow tumours to prosper.
But these pathways may also be vital to other clinical functions. With rising concern about
collateral cardiac damage from cancer treatment comes a call for a new partnership between
oncology and cardiology, to avoid problems and to treat them quickly and expertly if they do arise.
The number of drugs being developed to target specific mutations is rising steadily. But finding which targeted therapies work best for which sets of mutations is proving an elusive goal.
Clifford Hudis takes a look at how dose-dense regimens, intended to increase efficacy by decreasing the time between doses, work and effect toxicity in early breast cancer, especially where targeted agents are added.
With our new-found understanding of cancer biology comes the opportunity to explain a disease that for centuries has confounded doctors and engendered stigma and superstition. Siddhartha Mukherjee took that opportunity and turned it into a best seller.
Hodgkin's patients survive for longer Â– but with more serious and lasting damage Â– than almost any other group of cancer patients. Finding ways to address the problems of both current and future survivors can provide valuable lessons for other cancers.
Targeted drugs can result in a variety of skin toxicities that are unpleasant for patients and, if unattended to, can lead them to stop taking their drug as prescribed. Effective teamwork is required to ensure symptoms are identified and managed.
Since the concept of personalised cancer therapies first emerged, the picture has become so much more complex and challenging.
Nobel laureate Jim Watson is calling on the cancer community to take a long hard look at what has been achieved by blocking the molecular signals that drive individual cancers
Building a lung cancer team that works seamlessly to do the best for each patient was the biggest challenge in Enriqueta FelipÂ’s career. Her focus today is on increasing collaboration across Europe, which she sees as key if patients are to benefit quickly from the new opportunities offered by personalised therapies.
Could intelligent combinations of drugs and radiation take precision radiotherapy to new levels? Marcel Verheij believes so, but may struggle to prove it without a fairer share of funding
The side effects of targeted drugs are poorly documented, and their impact on patients frequently seriously underestimated and undertreated. Efforts to address these issues could improve survival as well as quality of life.
Recent years have seen a revival of interest in the unique metabolism of cancer cells. This time the focus is on the potential it offers as a target, rather than any possible causal role Â– but that link with obesity still needs explaining.
Early detection, disease prognosis, a guide to treatment, a key to unlock the secrets of how cancers evolve. Researchers have high hopes for what they can learn from the biological detritus shed by primary tumours and metastases.